Montag, 19. April 2021
Navigation öffnen

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer



Januar 2018

Letztes Update:

Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B)

Indikation (Clinical Trials):
Carcinoma, Adenocarcinoma, Carcinoma, Hepatocellular, Biliary Tract Neoplasms, Carcinoma, Ductal, Bile Duct Neoplasms, Cholangiocarcinoma


Erwachsene (18+)

Phase 2


SERVIER (Shire, Baxalta), Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH,


Thomas J. Ettrich, Dr.
Principal Investigator
Klinik für Innere Medizin I, Universitätsklinikum Ulm


(1 von 1)

Leberkrebszentrum Universitätsklinikum Ulm
Albert-Einstein-Allee 23
89081 Ulm
DeutschlandRekrutierend» Google-Maps
Thomas J. Ettrich, Dr.
» Ansprechpartner anzeigen


Detailed Description:

The primary objective is to determine whether a combination of 5-FU and nal-IRI prolongs progression-free survival in patients with locally advanced or metastatic adenocarcinoma of the biliary tract


Inclusion Criteria:

1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations

2. Age ≥ 18 years at time of study entry

3. Histologically confirmed, non-resectable, locally advanced or metastatic adenocarcinoma of the intrahepatic or extrahepatic biliary tract

4. Protocol-specific staging guidelines have to be observed and non-resectability has to be confirmed by local tumor board

5. Measurable or assessable disease according to RECIST 1.1

6. ECOG performance status 0-1

7. Life expectancy of more than 3 months

8. If applicable, adequately treated biliary tract obstruction before study entry with total bilirubin concentration ≤ 2 x ULN

9. Adequate blood count, liver-enzymes, and renal function:

- White blood cell count ≥ 3.5 x 10^6/mL

- Platelet count ≥ 100 x 10^9/L (>100,000 per mm3)

- AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal

- Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute

10. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization

11. No prior palliative chemotherapy for biliary tract cancer

12. No adjuvant treatment within 6 months prior to study entry

13. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

1. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes

2. Premalignant hematologic disorders, e.g. myelodysplastic syndrome

3. Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrollment

4. Prior (>5 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].

5. Pre-existing lung disease

6. History or clinical evidence of CNS metastases

Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:

1. are asymptomatic and

2. have no requirement for steroids 6 weeks prior to start of study treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases

7. History of hypersensitivity to any of the study drugs or any of the constituents of the products

8. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy

9. Severe non-healing wounds, ulcers or bone fractions

10. Evidence of bleeding diathesis or coagulopathy

11. Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.

12. Medication that is known to interfere with any of the agents applied in the trial.

13. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessary (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at Screening.

14. Known Gilbert-Meulengracht syndrome

15. Known chronic hypoacusis, tinnitus or vertigo

16. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

17. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is of longer duration.

18. Previous enrollment or randomization in the present study (does not include screening failure).

19. Any other chemotherapy at study start

20. Involvement in the planning and/or conduct of the study

21. Patient who might be dependent on the sponsor, site or the investigator

22. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.

23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.


Primary outcome:

1. Progression-free survival [PFS] (Time Frame - approx. 25 months)

Secondary outcome:

1. Overall progression free survival according to RECIST 1.1 (Time Frame - approx. 54 months):
Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)

2. 3-years overall survival (Time Frame - approx. 36 months):
3-years overall survival

3. Disease control rate according to RECIST 1.1 (Time Frame - approx. 54 months)

4. Objective tumor response rate (ORR) according to RECIST 1.1 (Time Frame - approx. 54 months):
Proportion of patients with an objective response according to RECIST 1.1

5. Toxicity/Safety according to CTC-AE-criteria (Time Frame - approx. 54 months)

6. Health related quality of life (Time Frame - approx. 54 months):

7. Health related quality of life (Time Frame - approx. 54 months):

8. Health related quality of life (Time Frame - approx. 54 months):
Hospital Anxiety and Depression Scale (HADS-D)

9. Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review (Time Frame - approx. 54 months):
Tumor resectability in accordance with a retrospective central surgical board compared to local surgical review

10. Retrospective central radiological review (Time Frame - approx. 54 months)


  • Experimental: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
    Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
  • Other: Arm Cisplatin + Gemcitabine (Arm B, standard of care)
    Cisplatin, Gemcitabine Cycle q3w

Geprüfte Regime

  • Arm NaI-IRI + 5-FU + Leucovorin (Arm A):
    Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
  • Arm Cisplatin + Gemcitabine (Arm B):
    Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w


Das könnte Sie auch interessieren
70 Prozent der Deutschen fürchten Tumor, Engagement für Gesundheit wächst
© pressmaster /

Sieben von zehn Menschen in Deutschland fürchten sich am meisten vor Krebs. Bei Erwachsenen zwischen 30 und 44 Jahren und Frauen ist die Angst besonders groß. Das zeigt eine aktuelle und repräsentative Studie der DAK-Gesundheit. Ein weiteres zentrales Ergebnis: Das Engagement für die eigene Gesundheit wächst. Immer mehr Menschen gehen zu Vorsorgeuntersuchungen und halten sich mit Sport und gesunder Ernährung fit.

Brustkrebs: Informationen helfen gegen Ängste
© Sebastian Kaulitzki /

Aktuelle Studien belegen: Patientinnen mit der Diagnose Brustkrebs profitieren von  guter Gesundheitsinformation und Aufklärung. Ängste und Sorgen nehmen ab, die Lebensqualität steigt. Der Krebsinformationsdienst (KID) des Deutschen Krebsforschungszentrums (DKFZ) informiert Betroffene und Angehörige seit 30 Jahren rund um das Thema Krebs. Bei 50 Prozent aller Anfragen zu Tumorlokalisationen steht das Thema Brustkrebs...